Table 3. Clinical characteristics and HRPT2/CDC73 mutations in subjects of control groups.

Case no.	Gender	History of PHPT(year)	Age at diagnosis of PHPT(year)	Size of tumor (cm)	Serum Ca (mmol/L)	Plasma iCa (mmol/L)	Serum P (mmol/L)	Serum ALP (U/L)	Serum PTH (×UL)
pa1	Male	0.5	50	4.5	3.02	1.55	0.65	112	8.5
pa2	Male	3	36	4	2.88	NK	0.55	2013	33.6
pa3	Male	0.17	38	1.5	3.05	1.46	0.81	54	4.4
pa4	Female	6	69	1.7	2.93	1.37	0.81	99	4.1
pa5	Male	20	52	2.5	3.03	1.49	0.68	72	6.4
pa6	Male	0.5	30	4	3.10	1.67	0.52	749	21.5
pa7	Male	1	42	3	3.40	1.76	0.81	109	7.4
pa8	Male	3	63	2.5	3.51	1.52	0.84	145	6.4
pa9	Female	1	63	2.5	3.51	1.40	0.83	146	31.5
pa10	Male	2	40	5	4.48	2.21	0.97	323	34.5
pa11	Female	6	41	5	3.10	1.73	0.65	1833	47.2
pa12	Male	10	60	3	3.15	1.62	0.81	1530	35.8
pa13	Male	8	54	1.8	2.86	1.34	0.96	105	6.8
ph1	Male	4	57	3	2.60	NK	0.94	103	3.7
ph2	Female	2	76	2	3.48	NK	0.61	85	6.6
ph3	Male	0.75	28	2.5	3.35	NK	0.61	80	10.3
ph4	Male	2	45	4	3.63	NK	0.45	178	31.2
ph5	Male	2	42	1.2	2.87	NK	0.39	NK	4.0
ph6	Female	6	67	2	2.90	1.53	0.90	200	20.0
ph7	Male	5	37	4	3.13	NK	0.77	154	21.5
NP1	Male	–	58	–	2.16	–	1.15	–	–
NP2	Male	–	46	–	2.21	–	1.41	–	–
NP3	Female	–	52	–	2.38	–	1.34	–	–
NP4	Female	–	52	–	2.36	–	1.14	–	–
NP5	Male	–	60	–	2.25	–	1.10	–	–
NP6	Female	–	50	–	2.28	–	1.13	–	–

pa: parathyroid adenoma; ph: parathyroid hyperplasia; NP: normal parathyroid; NK: not known; UL: upper limit.